- Home
- CNEY vs RDHL Comparison
CNEY vs RDHL Comparison
Compare CNEY & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNEY | RDHL |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 4.0M |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | CNEY | RDHL |
|---|---|---|
| Price | $0.69 | $1.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 455.9K | 38.4K |
| Earning Date | 02-13-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.71 |
| 52 Week High | $3.25 | $3.31 |
Technical Indicators
Market Signals| Indicator | CNEY | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 50.93 | 67.68 |
| Support Level | $0.54 | $0.79 |
| Resistance Level | $0.80 | $1.07 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 40.25 | 79.30 |
Price Performance
Historical ComparisonAbout CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.